Rapamycin vs metformin – how do they compare for longevity?
They're often mentioned together as geroprotector candidates, but they work differently and have very different evidence behind them in this Atlas. Rapamycin directly and potently inhibits mTORC1 (its primary target) and has 79 evidence-labelled studies here, including a systematic review of human data. Metformin inhibits mTORC1 only indirectly – mainly by activating AMPK, though it also acts on mTORC1 through AMPK-independent routes – and has just 6 studies in the Atlas, none of them a randomized trial for a longevity endpoint.
Mechanism: direct vs indirect
Rapamycin binds FKBP12, and the pair docks on mTOR's FRB domain next to the kinase's substrate cleft, directly blocking mTORC1 – a precise, well-characterized mechanism. Metformin's route to mTORC1 is murkier and is itself an open scientific question: it activates AMPK, an energy-sensor that inhibits mTORC1 upstream, but studies in the Atlas show metformin still suppresses hepatic gluconeogenesis in AMPK-null and LKB1-null mouse liver, and still inhibits mTORC1 in AMPK-null cells via the Rag GTPases – meaning at least part of its action bypasses AMPK entirely.
What the human evidence actually shows
- BAN2014 H – diabetic patients started on metformin had longer median survival than matched non-diabetic controls who weren't on the drug. Retrospective and observational – consistent with a benefit, but not proof of one, since diabetics who get prescribed and stay on metformin may differ from non-diabetics in other health-relevant ways.
- LEE2024 S – the Atlas's one systematic review of an mTOR-pathway drug for human aging covers rapamycin and its rapalogs – not metformin, reflecting how much further along the rapamycin evidence base is for this specific question.
The practical trade-off
Metformin has decades of safety data as an FDA-approved diabetes drug, is inexpensive, and is already prescribed off-label by some longevity-focused physicians – its safety profile is a real practical advantage. But the Atlas's evidence for metformin specifically extending healthy lifespan rests on one retrospective observational study, not a randomized trial. Rapamycin's mechanism is more direct and its dose-response in animal models better characterized, but comes with the mTORC2-linked side-effect profile covered on the side-effects answer page.
Related entities
Thank you. Your answer was counted anonymously.